+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Gene Therapy Market Forecasts from 2023 to 2028

  • PDF Icon


  • 152 Pages
  • October 2023
  • Region: Global
  • Knowledge Sourcing Intelligence LLP
  • ID: 5716732

The global gene therapy market is evaluated at US$4.264 billion for the year 2021 and is projected to grow at a CAGR of 19.29% to reach the market size of US$14.661 billion by 2028.

The rise in investment in gene therapy research and development, together with the growing incidence of diseases such as cancer, are the main drivers of the global gene therapy market's expansion. According to data published by the Open Government Data (OGD) Platform India, cancer cases have prevailed in recent years. In the year 2019, people suffering from cancer were 13, 58, 415 in India, which rose to 14, 61, 427 cancer cases in 2022. A considerable need for innovative therapeutic medications that could be useful for cancer therapy is predicted due to the rising incidence of cancer patients.

Conventional gene treatments target the immune system to improve remissions for patients with advanced-stage tumours due to the rising importance of immunotherapy in cancer treatment.

The FDA authorized Vyjuvek in May 2023 for the treatment of wounds in patients 6 months and older with dystrophic epidermolysis bullosa (DEB) and mutations in the collagen type VII alpha 1 chain (COLTA1) gene. Vyjuvek is a herpes simplex virus type 1 (HSV-1) vector-based gene therapy. Additionally, in April 2023, REGENXBIO Inc. stated that the FDA has awarded RGX-202, a potential one-time gene therapy for the treatment of Duchenne muscular dystrophy.

Increasing Research And Development Activities ‘

Top market players are concentrating on R&D and regional growth tactics for greater market penetration. As per the WHO data published in April 2023, the total gross domestic spending on research and development for healthcare as % of GDP was 0.07% for Western specific which is leading the market, America was 0.03% and for Eastern Mediterranean, it was just 0.01% of the total GDP.

Further, in August 2022, the FDA approved Bluebird Bio's BLUE.O gene therapy for use in the treatment of patients with a rare condition that needs routine blood transfusions. Each unit of the medication costs USD 2.8 million.

Oncolytic virotherapy research is supported by several highly attractive grants. For instance, the National Institutes of Health awarded the researchers at the Centre for Nuclear Receptors and Cell Signalling at the University of Houston a USD 1.8 million grant in July 2022 to study oncolytic virotherapy. Additionally, in June 2022, the phase 1 clinical trials for ImmunoAct's CAR-T (chimeric antigen receptor) therapy, which is used to treat certain forms of cancer were completed.

Elicera Therapeutics AB, a cell and gene therapy firm in clinical development, received financing from the European Innovation Council (EIC) Accelerator Programme in June 2022 for $2.67 million (€2.5 million). The market for cancer gene therapy is predicted to benefit significantly from rising medical funding. In December 2022, researchers in the UK treated a young kid with relapsed T-cell leukaemia using a novel sort of gene therapy. The use of this novel gene therapy has sparked expectations that it can treat major illnesses.

The United States in North America is an Expected Dominant Market

Cancer is one of the leading causes of death in the United States. In 2022, an estimated 1.9 million new cancer cases will be diagnosed in the United States, and 609, 000 people will die from cancer. The increasing incidence of cancer is driving the demand for new and innovative cancer treatments, such as gene therapy.

Consequently, there have been significant advances in gene therapy technology in recent years. These advances have made it possible to develop gene therapy treatments for a wider range of cancers. For example, in 2022, the FDA granted approval for Adstiladrin (nadofaragene firadenovec-vncg), an adenoviral vector-mediated gene therapy. It is intended for adults experiencing high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) presenting with carcinoma in situ (CIS), with or without accompanying papillary tumours.

Moreover, there is a growing investment in gene therapy research in the United States. This investment is being driven by the potential of gene therapy to cure cancer and other diseases. In 2022, the National Institutes of Health (NIH) awarded over $1 billion in funding for gene therapy research. Further driving this momentum is the favourable regulatory environment. The regulatory environment for gene therapy is generally favourable in the United States. The FDA has approved several gene therapy treatments for cancer, and it is expected to approve more in the coming years.

The escalating figures of new cancer cases in the USA from 2020 to 2022 - 18, 06, 590 to 18, 98, 160 to 19, 18, 030 - underscore the persistent and concerning prevalence of cancer. This trend accentuates the significance of advancements in cancer treatments, including gene therapy. The mounting need for innovative therapeutic interventions aligns with the potential growth of the gene therapy market in the USA. As the patient pool expands, there is a concurrent opportunity for the development and adoption of gene therapies targeting various types of diseases, potentially reshaping the landscape of treatment strategies in the coming years.

Key Developments

  • In an agreement signedin October 2022, Xcell Biosciences and aCGT Vector agreed to work together to manufacture and test cell and gene treatments for cancer patients. In June 2021, Tata Memorial Centre and Indian Institute of Technology researchers worked together to create "Chimeric Antigen Receptor T-cell, " a cutting-edge kind of gene therapy for the treatment of cancer.
  • In December 2022, Adstiladrin, a non-replicating adenoviral vector-based gene therapy, received FDA approval. It is indicated for treating adult patients with high-risk, Bacillus Calmette-Guérin (BCG)-refractory, non-muscle-invasive bladder cancer (NMIBC), with carcinoma in situ (CIS), with or without papillary tumours.


By Therapy Type

  • Ex Vivo
  • In Vivo
  • In Situ

By Vector Type

  • Viral
  • Non-Viral

By Technique Type

  • Gene Augmentation
  • Gene Inhibition
  • Specific Cell Kill

By Disease Type

  • Cancer
  • Heart Disease
  • Diabetes
  • HIV
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

Table of Contents

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline
2.1. Research Data
2.2. Sources
2.3. Research Design
3.1. Research Highlights
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
4.5. Product Pipeline
5.1. Introduction
5.2. Ex Vivo
5.3. In Vivo
5.4. In Situ
6.1. Introduction
6.2. Viral
6.3. Non-Viral
7.1. Introduction
7.2. Gene Augmentation
7.3. Gene Inhibition
7.4. Specific Cell Kill
8.1. Introduction
8.2. Cancer
8.3. Heart Disease
8.4. Diabetes
8.5. HIV
8.6. Others
9.1. Introduction
9.2. North America
9.2.1. By Therapy Type
9.2.2. By Vector Type
9.2.3. By Technique Type
9.2.4. By Disese Type
9.2.5. By Country United States Canada Mexico
9.3. South America
9.3.1. By Therapy Type
9.3.2. By Vector Type
9.3.3. By Technique Type
9.3.4. By Disese Type
9.3.5. By Country Brazil Argentina Others
9.4. Europe
9.4.1. By Therapy Type
9.4.2. By Vector Type
9.4.3. By Technique Type
9.4.4. By Disese Type
9.4.5. By Country Germany France United Kingdom Italy Spain Others
9.5. Middle East and Africa
9.5.1. By Therapy Type
9.5.2. By Vector Type
9.5.3. By Technique Type
9.5.4. By Disese Type
9.5.5. By Country Saudi Arabia Israel United Arab Emirates Others
9.6. Asia Pacific
9.6.1. By Therapy Type
9.6.2. By Vector Type
9.6.3. By Technique Type
9.6.4. By Disese Type
9.6.5. By Country China Japan South Korea India Australia Indonesia Thailand Taiwan Others
10.1. Major Players and Strategy Analysis
10.2. Vendor Competitiveness Matrix
10.3. Mergers, Acquisitions, Agreements, and Collaborations
10.4. Vendor Competitiveness Matrix
11.1. Shanghai Sunway Biotech Co. Ltd
11.2. Pfizer In
11.3. Astellas Gene Therapies, Inc.
11.4. Novartis Gene Therapies
11.5. MeiraGTx
11.6. San Rocco Therapeutics
11.7. American Gene Technologies
11.8. Lysogene
11.9. AVROBIO Inc
11.10. Adverum Biotechnologies Inc
11.11. Spark Therapeutics, Inc.

Companies Mentioned

  • Shanghai Sunway Biotech Co. Ltd
  • Pfizer In
  • Astellas Gene Therapies, Inc.
  • Novartis Gene Therapies
  • MeiraGTx
  • San Rocco Therapeutics
  • American Gene Technologies
  • Lysogene
  • Adverum Biotechnologies Inc
  • Spark Therapeutics, Inc.



Table Information